Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RIVITaLISe: Rituximab in SP-MS
NCT01212094Phase 2Terminated
- Sponsor
- National Institute of Neurological Disorders and Stroke
- Start
- Sep 2010
- Primary completion
- Dec 2015
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of rituximab in secondary-progressive multiple sclerosis (SPMS), sponsored by National Institute of Neurological Disorders and Stroke. Started Sep 2010; status: terminated.
02
Drugs
rituximab
03
Conditions
secondary-progressive multiple sclerosis (SPMS)
Beyond the preview
Go deeper on NCT01212094.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01212094.